Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14440681 | 1.00 | AR (0.49) | ARCYP2C19 | |
| SCHEMBL14440678 | 0.87 | AR (0.50) | ARCYP2C19 | |
| SCHEMBL5644339 | 0.87 | AR (0.50) | ARCYP2C19 | |
| SCHEMBL5642938 | 0.86 | AR (0.55) | ARCYP2C19 | |
| SCHEMBL14440682 | 0.86 | AR (0.55) | ARCYP2C19 | |
| SCHEMBL5642371 | 0.84 | AR (0.53) | ARCYP2C19 | |
| SCHEMBL14440688 | 0.84 | AR (0.53) | ARCYP2C19 | |
| SCHEMBL14440680 | 0.84 | AR (0.45) | ARCYP2C19 | |
| SCHEMBL5643253 | 0.84 | AR (0.45) | ARCYP2C19 | |
| SCHEMBL14440692 | 0.82 | AR (0.46) | ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256208-B2 | Monocyclic N-Aryl hydantoin modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-14 | — | — | US | disclosed |
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005049580-A1 | MONOCYCLIC N-ARYL HYDANTOIN MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | AR, NR5A1, CYP19A1 | AR 1/4885CYP2C19 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.